

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

Brilliant Violet 785™ anti-mouse TCR ? chain

RRID:AB_2810347

Type: Antibody

Proper Citation

BioLegend Cat# 109249, RRID:AB_2810347

Antibody Information

URL: http://antibodyregistry.org/AB_2810347

Proper Citation: BioLegend Cat# 109249, RRID:AB_2810347

Target Antigen: TCR beta chain

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785™ anti-mouse TCR ? chain

Description: This monoclonal targets TCR beta chain

Target Organism: mouse

Clone ID: Clone H57-597

Antibody ID: AB_2810347

Vendor: BioLegend

Catalog Number: 109249

Record Creation Time: 20250819T235623+0000

Record Last Update: 20250820T065258+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785™ anti-mouse TCR ? chain.

No alerts have been found for Brilliant Violet 785™ anti-mouse TCR α chain.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kim WJ, et al. (2025) Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. *Cell*, 188(13), 3422.

Rennen S, et al. (2025) Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways. *Cell reports*, 44(8), 116150.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Ward S, et al. (2025) The IL-33/ST2 axis and tissue Treg maintain epithelial homeostasis and restrain cancer development in the skin. *Cell reports*, 44(6), 115837.

Papaioannou S, et al. (2025) Protocol for isolating and purifying murine liver sinusoidal endothelial cells for in vitro culture and functional assays. *STAR protocols*, 6(1), 103554.

Sun J, et al. (2025) Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. *Cancer immunology research*, 13(3), 400.

Labiano S, et al. (2025) Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. *Cell reports. Medicine*, 6(7), 102204.

Kandasamy M, et al. (2025) Glycogen synthase kinase-3 is essential for Treg development and function. *Cell reports*, 44(9), 116256.

Jin M, et al. (2024) Dynamic allostery drives autocrine and paracrine TGF- β signaling. *Cell*, 187(22), 6200.

Ausejo-Mauleon I, et al. (2024) Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry. *STAR protocols*, 5(1), 102803.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. *Cancer cell*, 41(11), 1911.

Papaioannou S, et al. (2023) Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury. *Cell reports*, 42(8), 112836.

Giri R, et al. (2022) Secreted NF- κ B suppressive microbial metabolites modulate gut inflammation. *Cell reports*, 39(2), 110646.

Melo-Silva CR, et al. (2021) Resistance to lethal ectromelia virus infection requires Type I interferon receptor in natural killer cells and monocytes but not in adaptive immune or parenchymal cells. *PLoS pathogens*, 17(5), e1009593.